News from sanofi A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

Jul 31, 2018, 07:59 ETQ2 2018 Performance Positions Sanofi for New Growth Phase

Sanofi (NYSE: SNY; EURONEXT: SAN) Q2 2018 Change Change at CER H1 2018 Change Change at CER IFRS net sales reported €8,176m -5.7% +0.1% €16,074m...


Jul 30, 2018, 13:37 ETSanofi Ships First Flu Vaccines for 2018-2019 Season

Sanofi Pasteur, the vaccine division of Sanofi (EURONEXT: SAN) (NYSE: SNY), today shipped the first of its nearly 70 million flu vaccine doses to...


Jul 02, 2018, 06:00 ETSanofi to further accelerate its scientific presence with the opening of a Global R&D Operations Hub in Chengdu, China

Sanofi (EURONEXT: SAN) (NYSE: SNY) is launching a Global R&D Operations Hub with a specialized focus on digitalization and big data analysis in...


Jun 25, 2018, 08:01 ETSanofi presents results from the first head-to-head study comparing Toujeo® to insulin degludec

Sanofi (NYSE: SNY; EURONEXT: SAN) presented positive non-inferiority results of the BRIGHT study comparing its long-acting insulin Toujeo® to insulin ...


Jun 04, 2018, 02:15 ETNew England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma

The New England Journal of Medicine (NEJM) today published pivotal data from two trials evaluating cemiplimab in advanced cutaneous squamous cell...


May 22, 2018, 08:01 ETFDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes

The U.S. Food and Drug Administration (FDA) has accepted Sanofi's regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment ...


May 21, 2018, 02:15 ETNew England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma

The New England Journal of Medicine (NEJM) today published detailed results from two Phase 3 trials for the investigational use of Dupixent®...


May 17, 2018, 01:11 ETSanofi: Accelerating Future Breakthroughs Through Clinical Trials -- Part 2 of 3

For biopharmaceutical companies looking to streamline the clinical trial process, "big data" can be a big challenge. From complex genomics to the...


May 16, 2018, 08:00 ETDupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

A pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents (ages 12-17) met its primary...


May 14, 2018, 01:00 ETSanofi: Accelerating Future Breakthroughs Through Clinical Trials - Part 1 of 3

Clinical trials are the crucial link between a discovery in the research lab and a new treatment reaching patients. Regulatory authorities, like the...


May 02, 2018, 02:17 ETSanofi Named to DiversityInc's Top 50 Companies for Diversity®

The DiversityInc Top 50 list, issued yearly since 2001, recognizes the nation's top companies for diversity and inclusion management. Companies named ...


May 01, 2018, 07:00 ETSanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients

Sanofi (NYSE: SNY; EURONEXT: SAN) and Regeneron Pharmaceuticals, Inc. today announced they will lower the net price of Praluent® (alirocumab)...


Apr 25, 2018, 09:05 ETFDA accepts for review Supplemental Biologics License Application for 0.5 mL dose of Fluzone® Quadrivalent (Influenza Vaccine) in children 6-35 months of age

The U.S. Food and Drug Administration has accepted for review a supplemental Biologics License Application to expand the age indication of the 0.5 mL ...


Apr 05, 2018, 08:03 ETNew Sanofi insulin savings program aims to lower out-of-pocket costs for people living with diabetes

Sanofi's new Insulins VALyou Savings Program will seek to help lower out-of-pocket costs for people living with diabetes who otherwise would pay full ...


Mar 27, 2018, 07:01 ETNew survey reveals many misconceptions exist about allergies, illustrating the need for greater education

Every spring, allergies take control of the lives of millions of Americans, affecting their work, their family time and even how well they sleep at...


Mar 14, 2018, 07:50 ETTaking Cancer Research to the Summit

Cancer treatments have been the focus of enormous research investment for decades. Despite a wide range of discoveries and treatment advances, cancer ...


Mar 10, 2018, 09:02 ETSanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need

To help ensure more affordable and timely access to patients most in need, Sanofi (EURONEXT: SAN) (NYSE: SNY) and Regeneron Pharmaceuticals, will...


Mar 10, 2018, 09:00 ETPraluent® (alirocumab) Injection significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate

Sanofi (EURONEXT: SAN) (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. today announced that the ODYSSEY OUTCOMES trial met its primary endpoint,...


Feb 07, 2018, 07:38 ETSanofi Delivers 2017 Business EPS in line with Guidance

Sanofi (NYSE: SNY; EURONEXT: SAN) Q4 2017 Change Change at CER Change at CER/CS(2) 2017 Change Change at CER Change at CER/CS(2) IFRS net sales...


Dec 11, 2017, 13:40 ETFDA Approves Sanofi's Admelog® (insulin lispro injection)

The U.S. Food and Drug Administration (FDA) has approved Sanofi's Admelog®, the first follow-on insulin lispro to help people living with diabetes...


Dec 05, 2017, 07:55 ETSanofi and IBM Watson Health real-world analysis showed that individuals not achieving control on basal insulin within 12 months were unlikely to achieve control during the remainder of the two year study

The likelihood of responding to basal insulin in routine care in the U.S. declined rapidly when blood sugar control was not achieved within the first ...


Dec 04, 2017, 06:01 ETSanofi's Toujeo® met main objective in head-to-head study versus insulin degludec

Sanofi's Toujeo® met the primary study objective in the first large head-to-head clinical trial1, called BRIGHT study, comparing Toujeo with insulin...


Nov 30, 2017, 11:46 ETSwitching to Toujeo® in a real-world setting produced a similar number of severe low blood sugar events as insulin degludec

Adults with type 2 diabetes who switched their basal insulin therapy to Toujeo® or insulin degludec, experienced similar numbers of low blood sugar...


Nov 02, 2017, 08:19 ETSanofi: Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed

Sanofi (NYSE: SNY; EURONEXT: SAN) Q3 2017 Change Change at CER Change at CER/CS(3) 9M 2017 Change Change at CER Change at CER/CS(3) IFRS net sales...


Oct 11, 2017, 08:00 ETInternationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis

Today, Peter Moffat, Executive Producer of HBO's The Night Of, unveiled Understand AD: A Day in the Life in partnership with Sanofi, Regeneron...